Moderna is trading 4.75% down at $141.79 after Rothschild & Co. Redburn downgraded the shares to Sell from Neutral and raised its price target to $81 from $40, citing valuation concerns despite positive clinical-trial results.
- The downgrade was issued on September 3, 2026, and continued weighing on shares during September 4 trading.
- Broader markets were cautious following stronger-than-expected employment data and reduced Federal Reserve rate-cut expectations.